Figma Shares Indicated To Open $105/$110
Piper Sandler maintained its Overweight rating and $155.00 price target on Integer Holdings (NYSE:ITGR) on Tuesday, aligning with broader analyst sentiment. According to InvestingPro data, seven analysts have recently revised their earnings expectations upward, with price targets ranging from $140 to $158. The research firm cited the company’s manufacturing involvement in several high-growth medical device markets.
The firm identified Integer’s likely manufacturing portfolio through analysis of publicly available information, industry knowledge, and logical inference. According to Piper Sandler, Integer’s Cardio & Vascular business probably has broad exposure to products from Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT), along with key structural heart devices including Watchman, TriClip, and MitraClip.
Integer’s Cardiac Rhythm Management & Neuromodulation business likely supports most spinal cord stimulation devices and Inspire Medical (TASE:BLWV)’s Upper Airway Stimulation system, the research firm noted. These product relationships represent significant growth opportunities for the medical device manufacturer.
Piper Sandler estimates these identified products could contribute approximately 200 basis points annually to Integer’s growth through 2028, representing about one-quarter of the company’s projected topline expansion. The firm based this assessment on modeling that includes some assumptions about Integer’s manufacturing relationships.
The research firm expressed confidence that Integer’s strategic positioning in high-growth medical technology markets and its manufacturing role in several leading products could sustain the company’s performance for years to come. For deeper insights into Integer Holdings’ financial health and growth prospects, including exclusive Fair Value analysis and comprehensive metrics, explore InvestingPro, where you’ll find the detailed Pro Research Report covering what really matters about this $4.1 billion medical device manufacturer.
In other recent news, Integer Holdings Corporation reported impressive first-quarter results, surpassing analyst expectations. The company achieved revenue of $437.4 million, exceeding the consensus estimate of $428.7 million, with a 7% year-over-year increase. This growth was driven by a 17% rise in the Cardio & Vascular segment, aided by new product launches and acquisitions. As a result, Integer raised its full-year adjusted earnings per share (EPS) guidance to a range of $6.15 to $6.51, up from the previous consensus of $6.07.
Analysts at Citi have upgraded Integer’s stock from Neutral to Buy, increasing the price target to $140, citing strong first-quarter performance and robust sales growth. Truist Securities also raised Integer’s stock target to $150, maintaining a Buy rating, due to the company’s consistent organic growth and favorable financial performance. Additionally, Integer Holdings announced corporate governance changes, including amendments to its charter and bylaws, following a stockholder vote.
The company’s management transition was also highlighted, with current COO Payman Khales set to take over as CEO in October, while current CEO Joe Dziedzic will remain in an advisory role until March 2026. These developments reflect Integer’s strategic positioning and commitment to ongoing growth within the medical device industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.